The company will still fund clinical research.
The company says Amy Schulman, who was tapped to head up Pfizer vaccines business, is leaving, per mutual agreement.
Biogen Idec and JV partner Samsung are going into the biosimilars business.
A recent poll shows a strong desire among web-savvy patients to play a more active role in medical research.
The FDA wants more data for the proposed canagliflozin-metformin medication mix.
The Gray Lady surveys the landscape of attention deficit disorder marketing.
Galderma's reorg will mean fewer employees. Novartis is closing a Canadian plant.
The drugmaker and partner AstraZeneca say they can't find a comfortable pricing arrangement with German insurers.
Famous from his reality show, "The Osbournes," Jack narrates his life with MS in a web documentary series.
The Heath, Labor and Welfare ministry says a publisher passed off advertorials as articles.
State legal reps ask Commissioner Hamburg to overturn the approval.
The regulator tells farmers to limit antibiotic use.
The physician networking service rolled out a job-hunting service that brings the medical job search into the modern age and provides a revenue stream.
The FDA's Center for Drug Evaluation and Research released a preliminary year-in-review report that says the agency has cleared 26 new molecular entities this year.
The fine is for Pradaxa documents that have gone missing. The company is accused of hiding risk information about its blood thinner.
The FDA granted priority review for the experimental, all-oral Gaucher's disease treatment.
The $120.4-million deal is part of Savient's bankruptcy auction.
Vaccine LU AF20513 is the their third Alzheimer's collaboration.
A Penn State researcher thinks it can help women with menstrual cramps.
The HHS Secretary has some positive enrollment stats to share, but sentiment shows she and Obama need some reputation rehab.
The company expects to join the prescription weight-loss market by 2014's third quarter.
Pew Charitable Trust's proposed conflict of interest guidelines could mean even less face time for sales reps and less industry money for CME programs.
The Boston-based agency hopes the new department will allow teams a broader perspective.
Genentech has gone out of its way to keep doctors choosing Lucentis over cheaper Avastin, the paper reports, and they have little incentive to do otherwise.
The company released two financial scenarios. The key is generic Copaxone.
People asked, experts answered.
Danish police are investigating the drugmaker over its decision to wait two days before announcing the FDA's February rejection.
The bad-ad watchdog issued an untitled letter to drugmaker Duchesnay in November.
FDA panel briefing documents indicate concern remains over bladder cancer, as the drug dapagliflozin undergoes a second review Thursday.
Covidien is buying ingestible-camera company Given Imaging.
The company says Docnet is more than a social site—it's a hub that merges networking, research and financial (as in Sunshine) resources.
The retraction comes six months after researchers were fired over misrepresented data.
The government division is scrutinizing marketing information for three drugs.
Reports of a Dec. 5 deal between the US and China could deepen inspectors' reach.
The drug is priced at $28,000 a month, before add-ons like ribivarin and (possibly) interferon.
Their letter to CMS voices disagreement with the decision to make textbooks and journals reportable under the Sunshine Act.
A survey of US hepatologists signals pent-up demand exists for the paradigm-changing HCV treatment, but that not all patients will get the drug right away.
The drug failed to hit its Phase III targets.
Phase-IIIb study results indicate Lyxumia—which is approved abroad but not in the US—was "non-inferior" in terms of controlling blood sugar levels regardless of whether the shot was given before breakfast or later.
Novo's global diabetes study finds that only 29% of polled patients were asked what they thought about prescribed regimens.
Although doctors still like sales reps, Capgemini and Quantia's researchers find their appeal is on the decline, while digital is on the rise. While age is a factor, it's the workplace that's shaping physician preferences.
The company's new president and possible CEO is expected to have significant latitude to change things.
The trio will focus on using immune systems to attack cancer.
Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.
The commericalization/development deal covers up to six anti-cancer assets, and gives OncoMed a 50/50 US partnership over the experimental monoclonal antibody demcizumab.
Sanofi top-lined positive clinical data today from its investigational basal insulin, as it seeks to defend its position in this fast-growing segment.
AstraZeneca has been awarded $76 million in damages in a ruling over Apotex's sales of a generic version of Prilosec.
Impax Laboratories announced that it has reached an agreement with Purdue Pharma to settle patent litigation surrounding Impax's generic version of OxyContin.
Following a Warning Letter from the FDA, 23andMe has stopped marketing its DNA test.
Chronic disease patients seek online support and information, and show little love for branded websites.
The agency extended the review time for Biogen's Alprolix by three months.
Forest's cost-savings initiative is aimed at reducing operating expenses by $500 million, while Eisai said it's cutting 130 positions in the US and Europe.
Contrary to a claim by a Kentucky Republican congressman that he was assured by FDA that it would not approve new opioids unless they had abuse-deterrent formulations, the agency says it never made such a commitment.
Spectrum DNA says its genetic services are at the ready, even if 23andMe's are not.
The FDA said it's reviewing the available and related scientific information on the issue of reduced efficacy in heavier women.
The leukemia drug is staying on the market, but for a more restricted patient population.
Research suggests ADHD is becoming a regular fixture in adolescence. At the same time, publishers and startups have developed increasingly complex tools to separate patients from abusers.
Critics worry the talked-about approval plan could mean adverse events surface far too late.
The marketing watchdog's untitled letter says a direct mailer failed to disclose "material facts" from the warnings and precautions section of the PI.
A poll indicates new cholesterol guidelines won't shake up the statin market in 2014.
The drugmaker says interim trial data meets FDA review requirements and is hoping for June 2014 approval.
The FDA said it is requiring the removal of certain restrictions on prescribing and use of the diabetes drug Avandia.
Janssen's hepatitis C drug Olysio (simeprevir) offers modest benefit over standard of care, but resistance in a subgroup of patients could hinder broader uptake.
Regulators say the company has not received approval for the device's touted functions.
EU's CHMP offered a recommendation this week for Gilead's sofosbuvir while also agreeing in principle to give Biogen Idec's Tecfidera "new active substance" gives it 10 years of exclusivity.
An organ-donation campaign with a Brazilian football tie-in, and a UK managed-access company's series of documentary films, took top honors.
A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.
Fetterolf, joining as SVP of innovation, is reuniting with another Palio+Ignite veteran.
Summaries max out at 160 characters and most queries are clinical.
Actavis shrinks its staff by 30%, and Bayer reduces its California footprint.
The National Health Service is expected to have a $49-billion deficit by 2020.
Bernstein analyst Tim Anderson says Novartis has become a stealth player in the CDK-4/6 inhibitor competition.
The agency's bad-ad warning letter calls the new violations "particularly troubling."
The PBM encourages step-therapy to control costs.
The drugmaker revealed the data a year after stopping a Phase III trial.
The drugmaker's green light was paired with the EMA's decision that several thousand unreported AEs were no big deal.
ProPublica's deep-dive into Medicare brand-prescribing habits show brands make a dent in Medicare's budget.
Phase III clinical trial results underwhelm investors who feel on-market drugs offer better patient value.
The patient population is small, at around 3,000, but the expected price tag is $330,000 a year.
New results from its Phase II safety trial show the LDL-cholesterol lowerer was not associated with a major increase in adverse events vs. standard of care.
AbbVie released top-line results from its Phase III SAPPHIRE-1 study of its hepatitis C cocktail.
The company is rolling out two new clinical trials, and Phase I data suggests an antidote could be on its way.
The company is paying $2.5 billion over its DePuy hip replacements and $11 million in a lawsuit over its seizure drug Topamax.
The avatar, part of an app designed to assist caregivers, was chosen as the winner of the two-day competition.
Early clinical trial results indicate 81% of advanced melanoma patients survived for one year.
The agency says mobile traffic has more than doubled over the past 12 months.
The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.
The calculator meant to help doctors use the new cholesterol guidelines appears to be flawed.
New software is helping drugmakers troubleshoot clinical trials before recruitment.
EyeonFDA finds that, when it comes to black-boxed drugs' marketing materials, the FDA is more likely to issue Warning Letters than untitled letters.
Known as Breo Ellipta in the US, GlaxoSmithKline's Relvar Ellipta was approved by the EMA for asthma and COPD. The overall market is expected to continue to grow, but an NIH study indicates more patient conversations need to happen.
The drugmaker says it will not pursue regulatory review of its Phase III JAK2 inhibitor fedratinib.
The president says current subscribers will be able to keep their plans.
Domestic manufacturers are being pressured to offer domestic discounts to international clients.
The EMA is wading through thousands of comments and may push back its clinical trial transparency initiative.
The company's changes are no longer limited to R&D.
Reviewers supported the drug's approval, but concerns about REMS and clinical trial integrity indicate the vote was not a roaring endorsement.
Aggressive new recommendations for treating patients at high risk of cardiovascular disease could significantly alter the treatment landscape.
The company also has breakthrough therapy designations for CLL and Waldenstrom's macroglobulinemia.
The US-only recall amounts to less than 1% of the company's inventory.